Nrx Pharmaceuticals Stock Net Income
| NRXPW Stock | USD 0.05 0 3.73% |
NRx Pharmaceuticals fundamentals help investors to digest information that contributes to NRx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of NRx Stock. The fundamental analysis module provides a way to measure NRx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NRx Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -30.1 M | -31.7 M | |
| Net Loss | -36.1 M | -37.9 M | |
| Net Loss | -980.6 K | -1 M | |
| Net Loss | (3.98) | (3.78) | |
| Net Income Per E B T | 1.00 | 0.60 |
NRx | Net Income |
NRx Pharmaceuticals Company Net Income Analysis
NRx Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current NRx Pharmaceuticals Net Income | (30.15 M) |
Most of NRx Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NRx Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NRx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for NRx Pharmaceuticals is extremely important. It helps to project a fair market value of NRx Stock properly, considering its historical fundamentals such as Net Income. Since NRx Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NRx Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NRx Pharmaceuticals' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
NRx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, NRx Pharmaceuticals reported net income of (30.15 Million). This is 108.83% lower than that of the Biotechnology sector and 143.04% lower than that of the Health Care industry. The net income for all United States stocks is 105.28% higher than that of the company.
NRx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NRx Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NRx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NRx Pharmaceuticals by comparing valuation metrics of similar companies.NRx Pharmaceuticals is currently under evaluation in net income category among its peers.
NRx Fundamentals
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 | ||||
| Number Of Shares Shorted | 1.2 K | ||||
| EBITDA | (30.02 M) | ||||
| Net Income | (30.15 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 9.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Earnings Per Share | (6.25) X | ||||
| Beta | 1.27 | ||||
| Market Capitalization | 714.61 M | ||||
| Total Asset | 7.32 M | ||||
| Retained Earnings | (253.15 M) | ||||
| Working Capital | (12.16 M) | ||||
| Net Asset | 7.32 M |
About NRx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NRx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NRx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NRx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NRx Stock Analysis
When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.